Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced malignancies

被引：8
作者：
Saleh, Mansoor
Gutierrez, Martin E.
Subbiah, Vivek
Smith, David C.
Asatiani, Ekaterine
Lihou, Christine F.
Zhen, Huiling
Yeleswaram, Swamy
Ji, Tao
Nemunaitis, John
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-CT111
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT111
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Preliminary results of a dose escalation study of the Fibroblast Growth Factor (FGF) "trap" FP-1039 (FGFR1:Fc) in patients with advanced malignancies
    Tolcher, A.
    Papadopolous, K.
    Patniak, A.
    Heath, E.
    Weise, A.
    Prokop, T.
    Morrone, S.
    Zanghi, J.
    Keer, H. N.
    LoRusso, P.
    EJC SUPPLEMENTS, 2010, 8 (07): : 121 - 121
  • [22] Tinengotinib in patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory/relapsed cholangiocarcinoma
    Javle, M.
    Fonkoua, L. A. Kankeu
    Mahipal, A.
    Liao, C-Y.
    Fountzilas, C.
    Li, D.
    Pelster, M. S.
    Goel, S.
    Peng, P.
    Sun, C.
    Wang, H.
    Hennessy, K.
    Fu, X.
    Neo, L.
    Shan, Y.
    Huang, P.
    Wu, D.
    Wu, F.
    Fan, J.
    Piha-Paul, S. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S215 - S216
  • [23] PEMIGATINIB, A SELECTIVE INHIBITOR OF FIBROBLAST GROWTH FACTOR RECEPTORS (FGFR1, 2 & 3), HAS NO CLINICALLY RELEVANT EFFECTS ON ELECTROCARDIOGRAMS (ECG) IN PATIENTS WITH ADVANCED MALIGNANCIES.
    Gong, X.
    Ji, T.
    Liu, X.
    Asatiani, E.
    Feliz, L.
    Lihou, C.
    Rockich, K.
    Landman, R.
    Schock, S.
    Chen, X.
    Yeleswaram, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S44 - S44
  • [24] First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors
    James J. Harding
    Christiane Jungels
    Jean-Pascal Machiels
    David C. Smith
    Chris Walker
    Tao Ji
    Ping Jiang
    Xin Li
    Ekaterine Asatiani
    Eric Van Cutsem
    Ghassan K. Abou-Alfa
    Targeted Oncology, 2023, 18 : 181 - 193
  • [25] First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors
    Harding, James J. J.
    Jungels, Christiane
    Machiels, Jean-Pascal
    Smith, David C. C.
    Walker, Chris
    Ji, Tao
    Jiang, Ping
    Li, Xin
    Asatiani, Ekaterine
    Van Cutsem, Eric
    Abou-Alfa, Ghassan K. K.
    TARGETED ONCOLOGY, 2023, 18 (02) : 181 - 193
  • [26] First-in-human (FIH) study of TAS-120, a highly selective covalent oral fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors
    Kuboki, Y.
    Matsubara, N.
    Bando, H.
    Shitara, K.
    Yoh, K.
    Kojima, T.
    Ohno, I.
    Takahashi, H.
    Harano, K.
    Kondo, S.
    Hirai, H.
    Morizane, C.
    Doi, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA).
    Soria, Jean-Charles
    Strickler, John H.
    Govindan, Ramaswamy
    Chai, Seungjean
    Chan, Nancy
    Quiroga-Garcia, Vanesa
    Bahleda, Rastislav
    Hierro, Cinta
    Zhong, Bob
    Gonzalez, Martha
    Santiago-Walker, Ademi E.
    Parekh, Trilok V.
    Luo, Feng Roger
    Sullivan-Chang, Loretta
    Xie, Hong
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] Results From a Phase 1/2 Study of INCB050465, a Potent and Highly Selective PI3K delta Inhibitor, in Patients With Relapsed or Refractory B-Cell Malignancies
    Martin, Peter
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (04) : 9 - 10
  • [29] Preliminary Results from an Ongoing Phase 1/2 Study of INCB053914, a Pan-Proviral Integration Sites for Moloney Virus (PIM) Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies
    Byrne, Michael
    Donnellan, William
    Patel, Manish R.
    Zeidan, Amer M.
    Cherry, Mohamad
    Baer, Maria R.
    Fathi, Amir T.
    Kaplan, Jason
    Zhou, Feng
    Zheng, Fred
    Barbour, April M.
    Savona, Michael R.
    BLOOD, 2017, 130
  • [30] Phase 1/2 study of INCB054329, a bromodomain and extraterminal (BET) protein inhibitor, in patients (pts) with advanced malignancies
    Falchook, Gerald
    Talpaz, Moshe
    Mita, Monica
    Szmulewitz, Russ
    Piha-Paul, Sarina
    Harb, Wael
    Morgensztern, Daniel
    Kaplan, Jason
    Munster, Pamela
    Cornell, Robert F.
    Zheng, Fred
    Yeleswaram, Swamy
    Zhou, Gongfu
    Cassaday, Ryan
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
12345